Skip to main content
Premium Trial:

Request an Annual Quote

RPS Diagnostics Merges With Lumos Diagnostics

NEW YORK (360Dx) – RPS Diagnostics has merged with Lumos Diagnostics, the companies said today.

Terms of the transaction were not disclosed.

RPS, based in Sarasota, Florida, develops, manufactures, and markets point-of-care diagnostic tests, while Lumos, based in Carlsbad, California, is a full service point-of-care diagnostic development firm that was spun out of Australia-based Planet Innovation.

The resulting company will retain the Lumos name and be headquartered to Sarasota, while maintain operations in Carlsbad. Its initial focus will be on the international launch of RPS' FebriDx, a blood-based point-of-care test for identifying clinically significant underlying febrile acute respiratory infections (ARI) and aiding in the differentiation of viral and bacterial infections.

The test, which can help physicians assess patients' immune responses to acute respiratory infections in order to reduce the overuse of antibiotics, received CE marking in October. It is also cleared in Canada, Saudi Arabia, and Singapore.

"Using FebriDx to help triage outpatient ARI is a game changer because successful antibiotic stewardship requires the clinician to first rule out a clinically significant bacterial infection," RPS President and CEO Robert Sambursky, who will continue in these roles at the merged company, said in a statement. "In addition, access to novel Lumos Diagnostics reader technology will facilitate next-generation digital enhancements which will accelerate speed to results, allow for quantitation, and enhance objectivity of our branded product lines."